Protective effects of clioquinol on human neuronal-like cells: a new formulation of clioquinol-loaded PLGA microspheres for Alzheimer’s disease

References

• Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, Bush AI. (2008). Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron, 59, 43–55.
   PubMed Web of Science ®Google Scholar
• Andreasen N, Blennow K. (2002). Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer’s disease. Peptides, 23, 1205–1214.
   PubMed Web of Science ®Google Scholar
• Bareggi SR, Braida D, Pollera C, Bondiolotti G, Formentin E, Puricelli M, Poli G, Ponti W, Sala M. (2009). Effects of clioquinol on memory impairment and the neurochemical modifications induced by scrapie infection in golden hamsters. Brain Res, 1280, 195–200.
   PubMed Web of Science ®Google Scholar
• Blennow K, Vanmechelen E. (2003). CSF markers for pathogenic processes in Alzheimer’s disease: diagnostic implications and use in clinical neurochemistry. Brain Res Bull, 61, 235–242.
   PubMed Web of Science ®Google Scholar
• Brady JM, Cutright DE, Miller RA, Barristone GC. (1973). Resorption rate, route, route of elimination, and ultrastructure of the implant site of polylactic acid in the abdominal wall of the rat. J Biomed Mater Res, 7, 155–166.
   PubMed Web of Science ®Google Scholar
• Brunt KR, Fenrich KK, Kiani G, Tse MY, Pang SC, Ward CA, Melo LG. (2006). Protection of human vascular smooth muscle cells from H2O2-induced apoptosis through functional codependence between HO-1 and AKT. Arterioscler Thromb Vasc Biol, 26, 2027–2034.
   PubMed Web of Science ®Google Scholar
• Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI. (2001). Treatment with a copper–zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron, 30, 665–676.
   PubMed Web of Science ®Google Scholar
• Cole SL, Vassar R. (2007). The Alzheimer’s disease β-secretase enzyme, BACE1. Mol Neurodegener, 15, 2–22.
   Google Scholar
• Crouch PJ, Blake R, Duce JA, Ciccotosto GD, Li QX, Barnham KJ, Curtain CC, Cherny RA, Cappai R, Dyrks T, Masters CL, Trounce IA. (2005). Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci, 25, 672–679.
   PubMed Web of Science ®Google Scholar
• Curtain CC, Ali F, Volitakis I, Cherny RA, Norton RS, Beyreuther K, Barrow CJ, Masters CL, Bush AI, Barnham KJ. (2001). Alzheimer’s disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem, 276, 20466–20473.
   PubMed Web of Science ®Google Scholar
• Eruslanov E, Kusmartsev S. (2010). Identification of ROS using oxidized DCFDA and flow-cytometry. In: Armstrong D (Ed.), Advanced Protocols in Oxidative Stress II, Methods in Molecular Biology. New Jersey: Humana Press, pp. 57–72.
   Google Scholar
• Filiz G, Caragounis A, Bica L, Du T, Masters CL, Crouch PJ, White AR. (2008). Clioquinol inhibits peroxide-mediated toxicity through up-regulation of phosphoinositol-3-kinase and inhibition of p53 activity. Int J Biochem Cell Biol, 40, 1030–1042.
   PubMed Web of Science ®Google Scholar
• Frazza EJ, Schmitt EE. (1971). A new absorbable suture. J Biomed Mater Res, 5, 43–58.
   PubMed Web of Science ®Google Scholar
• Frebel K, Wiese S. (2006). Signalling molecules essential for neuronal survival and differentiation. Biochem Soc Trans, 34, 1287–1290.
   PubMed Web of Science ®Google Scholar
• Grandori C, Cowley SM, James LP, Eisenman RN. (2000). The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol, 16, 653–699.
   PubMed Web of Science ®Google Scholar
• Lee JY, Friedman JE, Angel I, Kozak A, Koh JY. (2004). The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging, 25, 1315–1321.
   PubMed Web of Science ®Google Scholar
• Masuda T, Hida H, Kanda Y, Aihara N, Ohta K, Yamada K, Nishino H. (2007). Oral administration of metal chelator ameliorates motor dysfunction after a small hemorrhage near the internal capsule in rat. J Neurosci Res, 85, 213–222.
   PubMed Web of Science ®Google Scholar
• Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, Cappai R, Masters CL, Tanzi RE, Inestrosa NC, Bush AI. (2002). Metalloenzyme-like activity of Alzheimer’s disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem, 277, 40302–40308.
   PubMed Web of Science ®Google Scholar
• Paterakis PG, Korakianiti ES, Dallas PP, Rekkas DM. (2002). Evaluation and simultaneous optimization of some pellets characteristics using a 3(3) factorial design and the desirability function. Int J Pharm, 248, 51–60.
   PubMed Web of Science ®Google Scholar
• Price KA, Crouch PJ, White AR. (2007). Therapeutic treatment of Alzheimer’s disease using metal complexing agents. Recent Pat CNS Drug Discov, 2, 180–187.
   PubMedGoogle Scholar
• Rauk A. (2009). The chemistry of Alzheimer’s disease. Chem Soc Rev, 38, 2698–2715.
   PubMed Web of Science ®Google Scholar
• Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL. (2003). Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol, 60, 1685–1691.
   PubMed Web of Science ®Google Scholar
• Ruijtera AJM, Meinsmaa RJ, Bosmab P, Kempa S, Carona HN, Kuilenburg ABP. (2005). Gene expression profiling in response to the histone deacetylase inhibitor BL1521 in neuroblastoma. Exp Cell Res, 309, 451–167.
   PubMed Web of Science ®Google Scholar
• Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. (1997). 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer’s disease. J Neurochem, 68, 2092–2097.
   PubMed Web of Science ®Google Scholar
• Skovrosky DM, Lee LM, Trojanowski JQ. (2006). Neurodegenerative diseases: new concepts of pathogenesis and their therapeutics implications. Annu Rev Pathol, 1, 151–179.
   PubMed Web of Science ®Google Scholar
• White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke DE, Holsinger RM, Evin G, Cherny RA, Hill AF, Barnham KJ, Li QX, Bush AI, Masters CL. (2006). Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem, 281, 17670–17680.
   PubMed Web of Science ®Google Scholar
• Yang Q, Owusu-Ababio G. (2000). Biodegradable progesterone microsphere delivery system for osteoporosis therapy. Drug Dev Ind Pharm, 26, 61–70.
   PubMed Web of Science ®Google Scholar
• Zahirul M, Khan I. (1996). Dissolution testing for sustained or controlled release oral dosage forms and correlation with in vivo data: challenges and opportunities. Int J Pharm, 140, 131–143.
   Google Scholar
• Zheng H, Weiner LM, Bar-Am O, Epsztejn S, Cabantchik ZI, Warshawsky A, Youdim MB, Fridkin M. (2005a). Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. Bioorg Med Chem, 13, 773–783.
   PubMed Web of Science ®Google Scholar
• Zheng H, Youdim MB, Weiner LM, Fridkin M. (2005b). Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons. Biochem Pharmacol, 70, 1642–1652.
   PubMed Web of Science ®Google Scholar
• Zhu X, Su B, Wang X, Smith MA, Perry G. (2007). Causes of oxidative stress in Alzheimer disease. Cell Mol Life Sci, 64, 2202–2210.
   PubMed Web of Science ®Google Scholar